PL1637141T3 - Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej - Google Patents

Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej

Info

Publication number
PL1637141T3
PL1637141T3 PL04022378T PL04022378T PL1637141T3 PL 1637141 T3 PL1637141 T3 PL 1637141T3 PL 04022378 T PL04022378 T PL 04022378T PL 04022378 T PL04022378 T PL 04022378T PL 1637141 T3 PL1637141 T3 PL 1637141T3
Authority
PL
Poland
Prior art keywords
serine protease
protease
composition
stabilized
reversible inhibitors
Prior art date
Application number
PL04022378T
Other languages
English (en)
Inventor
Lars-Olov Andersson
Hans Ageland
Original Assignee
Trobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trobio Ab filed Critical Trobio Ab
Publication of PL1637141T3 publication Critical patent/PL1637141T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
PL04022378T 2004-09-21 2004-09-21 Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej PL1637141T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04022378A EP1637141B1 (en) 2004-09-21 2004-09-21 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease

Publications (1)

Publication Number Publication Date
PL1637141T3 true PL1637141T3 (pl) 2012-04-30

Family

ID=34926632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04022378T PL1637141T3 (pl) 2004-09-21 2004-09-21 Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej

Country Status (8)

Country Link
US (2) US8394372B2 (pl)
EP (1) EP1637141B1 (pl)
AT (1) ATE533491T1 (pl)
DK (1) DK1637141T3 (pl)
ES (1) ES2377118T3 (pl)
IL (1) IL190024A0 (pl)
PL (1) PL1637141T3 (pl)
WO (1) WO2007035143A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EA030631B1 (ru) 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
IL229134A0 (en) 2013-10-29 2014-03-31 Omrix Biopharmaceuticals Ltd Compounds and methods for stabilizing thrombin activity
IL234246A0 (en) 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
CN108289867A (zh) 2015-07-02 2018-07-17 地平线孤儿病有限责任公司 Ado-抗性的半胱胺类似物和其用途
CN105181978B (zh) * 2015-09-23 2016-07-20 青岛古高生物科技有限公司 一种凝血酶时间测定试剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
US6440427B1 (en) * 1991-06-17 2002-08-27 Biovitrum Ab Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
TW217410B (pl) * 1992-04-01 1993-12-11 Ciba Geigy
US6177126B1 (en) * 1993-03-31 2001-01-23 Nycomed Arzneimittel Gmbh Process for the production of a material for sealing and healing wounds
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
EP0835931A4 (en) * 1995-06-26 2000-11-15 Daiichi Pure Chemicals Co Ltd STABLE PLASMINE SOLUTION
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
GB9821483D0 (en) * 1998-10-03 1998-11-25 Glaxo Group Ltd Chemical compounds
WO1999011657A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. 1-amino-7-isoquinoline derivatives as serine protease inhibitors
JP3796340B2 (ja) 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
JPH11164699A (ja) * 1997-12-05 1999-06-22 Kdk Corp トリプシンの安定化方法およびトリプシンの酵素活性向上方法並びにトリプシン酵素活性測定用キット
US7790192B2 (en) * 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2002003353A (ja) 2000-06-19 2002-01-09 Kansai Koso Kk メチオナーゼ及び／又はプロテアーゼ阻害剤及び口腔用組成物
DE60122750T2 (de) 2000-09-11 2006-12-21 Genentech, Inc., South San Francisco Amidin-Inhibitoren von Serin-Proteasen
AU2002231235A1 (en) * 2000-11-07 2002-05-21 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2003016347A1 (fr) 2001-08-09 2003-02-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Procede de preparation d'un fragment peptidique presentant une activite inhibitrice de mort cellulaire
CN1504580A (zh) 2002-11-28 2004-06-16 希森美康株式会社 凝血酶试剂以及检查试剂套装
JP2004191367A (ja) * 2002-11-28 2004-07-08 Sysmex Corp トロンビン試薬及び検査試薬キット
US6896809B2 (en) * 2002-12-20 2005-05-24 Providence Health System - Oregon Methods for purifying chitosan
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
US20060270014A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification

Also Published As

Publication number Publication date
US20130157339A1 (en) 2013-06-20
US20090136474A1 (en) 2009-05-28
EP1637141B1 (en) 2011-11-16
ES2377118T3 (es) 2012-03-22
ATE533491T1 (de) 2011-12-15
EP1637141A1 (en) 2006-03-22
DK1637141T3 (da) 2012-02-27
US8574569B2 (en) 2013-11-05
IL190024A0 (en) 2009-09-22
WO2007035143A1 (en) 2007-03-29
US8394372B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
WO2008109181A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
WO2005074643A3 (en) Benzamide compounds useful as rock inhibitors
EP1889842A4 (en) HETEROCYCLIC CONNECTION
DK1487444T3 (da) Anvendelse af pyridylamider som angiogeneseinhibitorer
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
SE0100902D0 (sv) Compounds
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
MY137830A (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2007056159A3 (en) Hydrazone derivatives and uses thereof
WO2004031145A3 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
WO2005005389A3 (en) Malonamide derivatives
IL190024A0 (en) Stabilized protease composition
EP1709037B8 (en) Hiv protease inhibiting sulfonamides
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
SE0103710D0 (sv) Compounds
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
WO2005058841A3 (en) Hiv protease inhibiting compounds
WO2005048922A3 (en) Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
WO2005061496A8 (en) Aminopyridine-derivatives as inductible no-synthase inhibitors
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.